Oncolytic virotherapy using reovirus is a promising new anti-cancer treatment with potential for use in humans and dogs. Because reovirus monotherapy shows limited efficacy in human and canine cancer patients, the clinical development of a combination therapy is necessary. To identify candidate components of such a combination, we screened a 285-compound drug library for those that enhanced reovirus cytotoxicity in a canine melanoma cell line. Here, we show that exposure to an inhibitor of the ataxia telangiectasia mutated protein (ATM) enhances the oncolytic potential of reovirus in five of six tested canine melanoma cell lines. Specifically, the ATM inhibitor potentiated reovirus replication in cancer cells along with promoting the lysosomal activity, resulting in an increased proportion of caspase-dependent apoptosis and cell cycle arrest at G2/M compared to those observed with reovirus alone. Overall, our study suggests that the combination of reovirus and the ATM inhibitor may be an attractive option in cancer therapy.
INTRODUCTION
Canine melanoma is among the most aggressive cancers, exhibiting the ability to readily metastasize to other organs such as the lung, lymph nodes, and liver. Naturally occurring canine melanoma is considered a pre-clinical model of human melanoma. 1, 2 Therefore, new therapeutic approaches with efficacy against canine cancers have potential for application in the treatment of human cancers.
Oncolytic virotherapy has been studied extensively in human cancers. In 2015, a gene-modified herpes simplex virus-1, talimogene laherparepvec (T-VEC), was approved by the U.S. Food and Drug Administration (FDA) as a treatment for melanoma in patients with unresectable lesions of the skin and lymph nodes. 3 Oncolytic viruses are considered attractive treatment options because such reagents are known to activate anti-tumor innate and/or adaptive immune effector cells. [4] [5] [6] [7] Indeed, multiple clinical trials have examined the efficacy against human cancers of oncolytic viruses in combination with chemotherapeutic drugs, radiation, and small molecule inhibitors. [8] [9] [10] New candidate drugs for use in combination therapy with oncolytic viruses for treating human cancers still need to be identified.
In the veterinary field, there have been only a limited number of reports regarding the use of oncolytic viruses against canine cancer, but several pre-clinical trials suggesting possible application in human medicine have been reported recently. [11] [12] [13] [14] Reovirus is a double-stranded RNA virus with low pathogenicity in humans. Our laboratory has previously reported that REOLYSIN, a good manufacturing practice (GMP)-grade non-modified reovirus serotype 3 Dearing strain reovirus, exhibits efficacy in the treatment of canine cancers including mast cell tumors, lymphoma, mammary gland tumors, and melanoma when tested in vitro and in vivo in mouse xenograft models. [15] [16] [17] [18] We also have carried out pilot clinical studies using REOLYSIN to treat 19 dogs with spontaneously occurring tumors, demonstrating that reovirus therapy was safe and welltolerated in tumor-bearing dogs. 19 Although decreased tumor volume was observed in some of the reovirus-treated dogs, complete tumor regression was not seen in any of the enrolled dogs. REOLYSIN has been used in multiple clinical trials in human cancer patients, primarily in combination with chemotherapeutic agents, with the intent of enhancing the efficacy of oncolytic therapy. 10, 20 In general, other therapeutic options are needed to enhance reovirus oncolysis for the treatment of dogs and humans with tumors. Therefore, the objective of our current study was to develop a new combination approach for oncolytic virotherapy using reovirus in canine cancers. By screening a large number of small molecule inhibitors in combination with reovirus, we successfully identified a novel inhibitor of the ataxia telangiectasia mutated protein (ATM). Here, we report the first evidence to our knowledge that the cytotoxicity of reovirus is potentiated by inhibition of ATM in canine melanoma cell lines. We also show that ATM inhibition increases reovirus replication, endosomal acidification, and cathepsin B activity. Notably, reovirus was able to induce the phosphorylation of ATM without inducing DNA damage. Thus, our study demonstrated that the combination of reovirus and an ATM inhibitor may be an attractive option in cancer therapy.
RESULTS

The Combination of an ATM Inhibitor and Reovirus Enhances Anti-tumor Effects in Cell Lines
To identify drugs that enhance reovirus-induced anti-tumor effects, we screened a 285-compound signaling pathway inhibitor library for activity in the CMeC1 canine melanoma cell line ( Figure S1 ). This screen revealed that the ATM inhibitor KU55933 showed no effect on cell proliferation by itself but potentiated the cytotoxicity of reovirus when used in combination with reovirus. Moreover, the combination of KU55933 and reovirus yielded dose-dependent suppression of CMeC1 cell growth ( Figure S2 ). For subsequent experiments, a higher specificity inhibitor of the ATM, KU60019 21 was used in place of KU55933.
To confirm if KU60019 enhances reovirus-induced anti-tumor effects in other types of canine melanoma cell lines, we also examined in vitro cell survival using another five canine melanoma cell lines ( Figure 1 ). KU60019 combined with reovirus (MOI 100) significantly suppressed cell proliferation in CMeC1, KMeC, CMM12, LMeC, and CMM10 cell lines, as shown with KU55933. These results indicated that the combination of KU60019 and reovirus yielded significant cell growth inhibition compared to compound or virus alone in five of six tested canine melanoma cell lines excepting CMGD2. These data provided evidence that combination treatment with reovirus and ATM inhibitor potentiated anti-tumor activity in canine melanomas.
To confirm the specificity of the ATM inhibitor, the ATM-encoding gene was knocked out in several canine melanoma cell lines (CMeC1, KMeC, CMM10, and CMM12) using a CRISPR/Cas9-based system (Figure 2A ). At 48 h after infection with reovirus, ATM knockout cells showed greater inhibition of cell viability than did the respective ATM + cells ( Figure 2B ). Whereas the ATM knockout did not influence on the cell growth in CMeC1 and CMM10 compared to ATM + (wild-type) cells, but the growth of KMeC and CMM12 were suppressed to some extent ( Figure S3 ). These results supported that inhibition of ATM sensitizes canine melanoma cell lines to reovirus-induced cytotoxicity.
KU60019 Enhances Reovirus-Induced Apoptosis and Cell Cycle Arrest
Next, we assessed the potential mechanism by which the combination of KU60019 and reovirus induces anti-tumor effects. In addition to cell proliferation assay, cell viability was examined in four of these cell lines (CMeC1, KMeC, LMeC, and CMGD2) by means of a trypan blue exclusion test ( Figure 3A ). Compared to reovirus alone, the combination of KU60019 and reovirus strongly potentiated cell death in three of the four canine melanoma cell lines, excepting CMGD2. At the earlier time point (24 h), cleaved caspase-3 accumulated to higher levels in CMeC1 cells subjected to the combination treatment than in the same cell line treated with reovirus alone ( Figure 3B ). As expected, the percentage of sub-G1 cells increased from 24 h to 48 h in CMeC1 cells subjected to the combination treatment compared to the percentage in cells treated with reovirus alone ( Figure 3C ). Notably, pre-treatment of CMeC1 and KMeC with 50 mM Z-VAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone, an irreversible caspase inhibitor), before exposure to the combination of reovirus and KU60019, resulted in the complete inhibition of reovirus-induced cell death, as assessed by the trypan blue exclusion test ( Figure 3D ). However, in a cell proliferation assay, the combination treatment was not sufficient to completely abrogate cell growth in either of these cell lines ( Figure 3E ). Therefore, we inferred that the To evaluate cell proliferation, canine melanoma cell lines (CMeC1, KMeC, LMeC, CMM10, CMM12, and CMGD2) were treated with reovirus (MOI 100 for all cell lines except CMGD2 at MOI 10) and KU60019 (indicated concentration) for 48 h before adding CCK-8 reagent. Data are expressed as the mean ± SD from at least three independent experiments. p values were calculated for the comparison between reovirus alone and reovirus combined with KU60019. To focus on the additional effects provided by KU60019, significance was tested only where no significant difference was observed between mock control and KU60019 alone. Tukey-Kramer test, *p < 0.05, **p < 0.01. combination of reovirus and KU60019 also affects cell cycle progression in canine melanoma cells.
Consistent with previous studies showing that reovirus infection results in cell cycle arrest at G2/M in several cancer cell lines, [22] [23] [24] [25] [26] we observed that treatment with reovirus alone induced cell cycle arrest at G2/M in CMeC1. Moreover, treatment of CMeC1 with the combination of KU60019 and reovirus resulted in strong cell cycle arrest at G2/M and a reduction of the G1 interval ( Figure 4A ). In a previous report, the viral nonstructural protein sigma 1 s regulated the activity of CDK1 (the G2/M cyclin-dependent kinase; cdc2), which was required for cell cycle arrest at G2/M. 23 We sought to extend that analysis by using immunoblotting to test treated cells for their levels of CDK1 and p21 (the cyclin-dependent kinase inhibitor) ( Figure 4B ). After 24 h, cells treated with the combination of KU60019 and reovirus accumulated significantly lower levels of CDK1 than cells treated with either reagent alone. In contrast, the 24-h levels of p21 did not differ significantly among cells treated with the combination or with KU60019 or reovirus alone. Together, these results indicated that the treatment of canine melanoma cells with the combination of KU60019 and reovirus induces both caspase-dependent apoptosis and cell cycle arrest at G2/M.
KU60019 Increases Reovirus Replication and Progeny Virus Number
Next, we assessed the correlation between reovirus replication and anti-tumor effects in canine melanoma cell lines. Western blotting detected reovirus proteins in reovirus-infected CMeC1 and KMeC cells and further revealed that combination treatment (i.e., reovirus infection in the presence of KU60019) yielded increased levels of these proteins at each time point ( Figure S4 ). This analysis was extended by quantifying the progeny virus in the supernatant using the 50% tissue culture infectious dose (TCID 50 ) assay. In three of four tested canine melanoma cell lines (CMeC1, KMeC, and CMGD2, but not in LMeC), the combination treatment yielded apparent increases in the number of progeny viruses compared to the input titer ( Figure 5A ). There was no statistical significance between reovirus alone and combination of KU60019 because the fold increase of virus titer was modest. To prove that viral replication is involved in the cell death effect of the combination of reovirus and KU60019, we used western blotting to assess the accumulation of reovirus structural proteins and cleavage of caspase-3 in CMeC1 subjected to the combination treatment in the presence of ribavirin, an anti-viral reagent. 27 Notably, ribavirin treatment completely suppressed both reovirus replication and caspase-3 cleavage ( Figure 5B ).
The Combination of KU60019 and Reovirus Does Not Enhance Reovirus Entry
To investigate the biological roles and functions of ATM in the reovirus replication cycle, each step of the replication cycle was analyzed during the treatment with reovirus and ATM inhibitor. The upregulation of junction adhesion molecule (JAM)-A, the reovirus receptor, might be associated with sensitivity to virusinduced cell death. 28, 29 The surface expression level of JAM-A was stable on cells treated with KU60019 for 1 h and 24 h by flow cytometric analysis ( Figure S5 ). This data indicated that KU60019 did not influence the step of virus entry.
In addition to testing whether the effect of ATM inhibition was mediated via the proteolytic step of reovirus replication, we examined the enhancement of viral protein expressions using protease-stripped reovirus virions (infectious subviral particles, ISVPs), which are capable of infecting cells lacking virus receptors and cells that have lost their ability to un-coat incoming virions. [30] [31] [32] As shown in Figure 5C, combination treatment of reovirus and KU60019 enhanced the expression of reoviral proteins at 12 and 24 h compared to cells exposed to reovirus alone. In contrast, subsequent western blotting ( Figure 5D ) demonstrated that KU60019 showed no effect on reoviral protein expressions after addition of ISVPs at early time points (at 6 h and 12 h), indicating that KU60019 influences an event before viral disassembly. However, at 24 h, reovirus protein levels were elevated in CMeC1 cells treated with the combination of KU60019 and ISVPs; at 48 h, the combination treatment yielded significant potentiation of cell growth inhibition compared to either component alone ( Figure S6 ), in parallel to the results of Figure 1 . We infer that this delayed effect (at 24 h and after) reflects the production of and infection by intact virus after one replication cycle (approximately 18 h 33 ), given that the production of intact virus was potentiated by the combination treatment. These results suggested that outer capsid proteins and the ATM inhibition during the reovirus life cycle might trigger the enhancement of virus replication.
Reovirus Infection Induces the Phosphorylation of ATM without Phosphorylation of DNA Damage-Related Proteins
Infection by some viruses has been shown to induce phosphorylation of ATM, resulting in the induction of DNA damage; [34] [35] [36] however, the mechanism linking ATM activity to replication of mammalian reovirus remains unclear. At an early stage of infection (12 h), reovirus induced phosphorylation of ATM in cell line CMeC1, but this modification was abrogated by KU60019 ( Figure 6 ). In addition, we examined whether reovirus induced DNA damage in cancer cells by determining the phosphorylation state of p53, which is known to be regulated by ATM and is known to detect DNA damage. 37 Notably, reovirus did not induce phosphorylation of p53 in a canine melanoma cell line ( Figures S7) . This observation suggested that reovirus infection leads to increases in the phosphorylation of ATM in cancer cells without associated DNA damage, leading to the enhancement of reovirus replication.
Endosomal Acidification and Protease Activity by the Combination of KU60019 and Reovirus
For early phase of infection, disassembly of the reovirus particle in the endosome is required for the replication cycle following internaliza-tion of the virus and depends on acidification of the endosome. 38, 39 To analyze the effect of the ATM inhibitor on the pH of the endosome, we used LysoTracker red, a dye that exhibits increased fluorescence at the low pH typical of endosomes, lysosomes, or authophagosomes ( Figures 7A and 7B ). Although the fluorescence intensity of LysoTracker red was not significantly altered compared to mock-treated cells following treatment with either reovirus or KU60019 alone, fluorescence was significantly increased with the combination treatment ( Figure 7B ). Confocal microscopy confirmed this result, showing that the number of LysoTracker-positive dots was elevated in cells treated with combination of reovirus and KU60019 ( Figure 7B ). These data suggested that the combination treatment potentiated the acidification of endosomes and lysosomes.
The endosomal acidification modulates the activity of some proteases such as cathepsins. [39] [40] [41] Therefore, we evaluated the cathepsin B activity in CMeC1 cells treated as in the above experiments. Unexpectedly, there was little difference in the cathepsin B activity between cells treated with KU60019 for 1 h and combination treatment of reovirus (data not shown). Cells exposed to reovirus alone for 24 h incubation exhibited nominal decreases in cathepsin B activity, although the effect fell short of significance (p = 0.06 compared to mock-treated cells; Figure 7C ). However, combination treatment restored the level of cathepsin B activity to a value similar to that seen with mock treatment. Even though the effect of the simultaneous treatment with reovirus and KU60019 on cathepsin B activity remains unclear, these results implied that the effect of KU60019 treatment is mediated by enhanced lysosomal activity in the late phase of infection. Thus, combination treatment potentiated the decreased pH in endosomes and lysosomes, followed by activating proteases, but was not committed to enhancing viral proteolysis at the virus entry step during the first round of viral infection.
DISCUSSION
In this study, we screened a drug library to identify new drugs that enhance reovirus cytotoxicity. As a result, we identified an ATM inhibitor. Previous reports demonstrated that many kinds of anticancer drugs have synergistic anti-tumor effects on cancer cells when combined with reovirus. 6, 26, [42] [43] [44] [45] However, the present work represents the first report to our knowledge that an ATM inhibitor can be used as a combination drug with reovirus treatment. Based on our observations, the combinatorial effects of reovirus and the ATM inhibitor resulted in reovirus-related apoptosis and cell cycle arrest at G2/M in most canine melanoma cell lines, with the exception of CMGD2 (a canine melanoma line). The specificity of the ATM inhibitor in our study was supported by a cell survival assay that treated ATM knockout canine melanoma cell lines with reovirus. Canine melanoma knockout cell lines exhibited higher susceptibility to reovirus compared to the isogenic wild-type (ATM + ) cell lines. However, the cell growth inhibition of reovirus combined with KU60019 was higher than that of reovirus with ATM knockout. We hypothesize that KU60019 inhibits not only ATM but also other kinases (mem- [PIKK] family), 21 in a dose-dependent manner, leading to high-efficiency virus replication and cytotoxicity.
We further examined the effect of the combination treatment on the ATM phosphorylation that is associated with reovirus replication in cancer cells. These experiments were inspired by observations of the effects of human herpes simplex virus-1 (HSV-1), hepatitis C virus, and human immunodeficiency virus-1 infection in other cell lines. [46] [47] [48] [49] For those viruses, ATM activation along with DNA damage supports viral replication, such that the inhibition of ATM negatively regulates replication. In contrast, it was unknown whether ATM activation is associated with mammalian reovirus replication. We are aware of only one relevant report, which demonstrated that two ATM-deficient cell lines (L3 lymphoblastoid cells and Granta mantle cell lymphoma cells) were more susceptible to reovirus than were other cell lines. 50 However, the relationship between reovirus replication, oncolysis, and ATM deficiency was not proven in that study. Therefore, in the present work, we identified a putative mechanism for the potentiation of reoviral oncolysis by the normal status and knockout of ATM. Interestingly, p53 phosphorylation, a marker of DNA damage, was not observed in canine melanoma cells even though reovirus infection might trigger unknown nuclear damage followed by activation of ATM. To confirm the biological roles and functions of ATM in the reovirus replication cycle, each step of the replication cycle was analyzed. We found that inhibition of ATM enhanced the endosomal acidification and re-activation of protease only in the late phase of reovirus infection. Previous work has shown that endosomal acidification and protease activity are essential for reovirus replication in early time points; 31,39,51 therefore, there might be another mechanism. Reoviridae family members, including mammalian reovirus, facilitate the induction of autophagy, and its autophagy elevates the virus replication. [52] [53] [54] [55] To assess the effect of combination treatment of KU60019 and reovirus on autophagy, we have examined the expression levels of the autophagy marker LC3B-II (the lipidated form of LC3B) in CMeC1 and KMeC by western blotting (data not shown). As a result, the accumulation of LC3B-II was observed in canine melanoma cells treated with reovirus alone at 24 h and 48 h, and then treatment of reovirus with KU60019 increased the LC3B-II expression. Although the overall mechanism of virus replication induced by ATM inhibition remains unclear, these data suggested that, at the late phase of infection, combination of reovirus and KU60019 facilitates the induction of autophagy (i.e., the upregulation of cathepsin B activity, the acidification of endosomes and lysosomes, and the LC3B-II accumulation), which might be associated with enhancement of virus replication.
Compared to KU55933 (the library-identified compound), KU60019 has greater specificity and is considered a much improved ATM kinase inhibitor. However, neither KU55933 or KU60019 are suitable for in vivo studies, given the low aqueous solubility and low bioavailability of these compounds. [56] [57] [58] The ATM inhibitor AZD0156 was recently reported 57 and shown to exhibit superior pharmacokinetics with the potential for oral dosing; this compound is the subject of an ongoing phase I clinical trial being performed by AstraZeneca. We hope to evaluate the combination of reovirus and AZD0156 in xenograft mice harboring canine melanoma cell lines.
A B D C
Taken together, our results suggested that the ATM inhibitor KU60019 enhances reovirus-induced anti-tumor effects in canine cancers (Figure 8 ). This synergy may provide a route to resolving the limited efficacy of reovirus treatment of cancers. Although the mechanism linking ATM activity, endosomal acidification, and reovirus replication remains unknown, we confirmed that treatment with the ATM inhibitor upregulated viral replication, resulting in increased the cell death. Given that the incidence of adverse events may be increased in combination treatment, in vivo experiments (e.g., mouse xenograft studies) will be needed to test this combination therapy. Nonetheless, these findings support further investigation of this combination therapy for the treatment of canine cancer patients.
MATERIALS AND METHODS
Cell, Reovirus, and Inhibitors
Seven canine malignant melanoma cell lines (CMeC1, KMeC, LMeC, 59 CMGD2, 60 CMM10, and CMM12 61 ) were used in this study. Five of the canine cell lines (CMeC1, KMeC, LMeC, CMM10, and CMM12) were kindly provided by Dr. T. Nakagawa (University of Tokyo, Tokyo, Japan). CMGD2 was kindly provided by Dr. J. Modiano (University of Minnesota, Minneapolis, MN, USA). A mouse L929 fibroblastic cell line (used for the titration of viral progeny) was obtained from the Cell Resource Center for Biomedical Research (Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan). All cell lines were grown in R10 complete medium (RPMI1640 supplemented with 10% fetal bovine serum [FBS], 100 U/mL penicillin, 100 mg/mL streptomycin, and 55 mM 2-mercaptoethanol) and maintained at 37 C in a humidified 5% CO 2 incubator.
The Dearing strain of reovirus serotype 3 (Reolysin; GMP-grade reovirus) was obtained from Oncolytics Biotech (Calgary, Canada). ISVPs were produced just before use and were generated according to the protocol of Alain et al. 30 In brief, reovirus (2.835 Â 10 8 plaque-forming units [PFU]) was digested with chymotrypsin-HCl (2 mg; Roche Diagnostics, Tokyo, Japan) for 30 min at 37 C. The digestion was terminated by adding phenymethylsulphonyl fluoride (5 mM in ethanol) and shifting the reaction to 4 C.
The ATM inhibitors KU55933 and KU60019 were obtained from AdooQ Bioscience (Irvine, CA, USA).
Drug Screening
To identify the new combination drug, we screened the SCADS inhibitor kit (Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan), which includes 285 signaling pathway inhibitors. The canine melanoma cell line CMeC1 (5,000 cells/well) was plated in 96-well plates containing each inhibitor, with or without reovirus at an MOI of 100 PFU per cell, and the plates were incubated for 48 h. After treatment, cell growth inhibition was evaluated by use of the cell counting kit-8 (CCK-8; Dojindo, Kumamoto, Japan) according to the manufacturer's instructions.
Cell Survival Assay
Each cell line was seeded at the density of 5,000 cells (CMeC1, KMeC, LMeC, CMGD2, and CMM12) or 10,000 cells (CMM10) in triplicates in 96-well plates and mock-infected or infected with reovirus at an MOI of 10 or 100 PFU per cell in the presence of the ATM inhibitor KU60019 at 1.25, 2.5, 5.0, or 10 mM; assays were performed in triplicate wells. Cells were cultured for 48 h before adding the CCK-8 reagent. The cell proliferation rate was calculated by measuring absorbance. In the cytotoxicity assay, each cell line was treated with reovirus at an MOI of 100 PFU per cell and KU60019 at 2.5 or 10 mM; assays were performed in triplicate wells. Cells were cultured for 48 h before performing the trypan blue exclusion test.
To assess the inhibition of apoptosis induced by treatment with reovirus and inhibitor, canine melanoma cell lines (CMeC1 and KMeC) were seeded at 5,000 cells per well in 96-well plates. The irreversible pan-caspase inhibitor, Z-VAD-FMK (Calbiochem, Billerica, MA, USA) was added to triplicate wells at a concentration of 50 mM for 1 h before the cells were treated with reovirus (MOI 100) and KU60019 (indicated concentration). After 48 h, cell proliferation and cell viability were evaluated by CCK-8 and trypan blue exclusion test, respectively.
All experiments were repeated at least three times. 
Reovirus Replication and Progeny Virus
Reovirus replication was examined by western blotting analysis using anti-reovirus antibody (produced by our laboratory [15] [16] [17] [18] ). Cell lines were seeded at 3 Â 10 5 cells per well in 6-well plates and treated with reovirus (MOI 100) and KU60019 (2.5 mM) for 24 and 48 h. In some experiments examining the reovirus proteins at early stages, wells were rinsed to remove unbound reovirus following adsorption. In brief, CMeC1 was plated at 5 Â 10 5 cells per well in 6-well plates and cultured before use. On the following day, cells were exposed to reovirus (MOI 100) or ISVPs (MOI 10) for 1 h at 4 C. Then, cells were washed and cultured in the presence of KU60019 (2.5 mM) for 6, 12, or 24 h at 37 C. Cells were harvested at the indicated time points and stored at À80 C pending use for western blotting.
Supernatants of the samples from the cytotoxicity assay were collected and stored at À80 C pending use. Viral progeny in the supernatants were measured using the 50% tissue culture dose (TCID 50 ) assay on L929 cells, as previously described. [15] [16] [17] [18] Titration of the viral progeny was performed on all the supernatants obtained from three independent cytotoxicity assays.
Genome Editing
A small guide RNA (sgRNA) targeting canine ATM, 5 0 -TAGTTT CAGGATCCCGAATC-3 0 , was designed through the online CRISPR design tool (http://zlab.bio/guide-designresources); the resulting sgRNA was synthesized and subcloned into the lentiCRISPRv2 plasmid, which was a gift from Dr. Feng Zhang 62 (obtained from Addgene [Cambridge, MA, USA] as accession #52961). The plasmid and packaging vectors were transfected to HEK293T to produce the lentivirus expressing an sgRNA targeting ATM. After transduction with the lentivirus, canine melanoma cell lines were cultured in the presence of puromycin (Sigma Aldrich Japan, Tokyo, Japan; 0.6-5.0 mg/ml) to select for stably transduced cells. Individual clones were isolated by the limiting dilution method and further analyzed by western blotting to confirm that the cells no longer produced ATM protein. The resulting clones were used for further experiments.
Flow Cytometric Analysis
To assess the cell cycle distribution, canine melanoma cells (3 Â 10 5 cells/well in 6-well plates) were treated with reovirus (MOI 100) and KU60019 (2.5 mM) for 24 and 48 h. Cells were trypsinized and washed in PBS and fixed in 70% ice-cold ethanol at À30 C for at least 24 h. The fixed cells were re-suspended in PBS supplemented with 0.1 mg/mL of RNase (Nacalai Tesque, Kyoto, Japan) and incubated for 30 min at room temperature. The digested cells then were incubated with 0.1 mg/mL of propidium iodide (PI; Nacalai Tesque) for 5 min and analyzed.
To evaluate surface expression of reovirus receptor JAM-A, a canine melanoma cell line (CMeC1) was seeded at 2 Â 10 5 cells per well in 12-well plates and treated with mock and KU60019 (2.5 mM) for 1 h or 24 h. Incubated cells were stained with primary antibodies including mouse immunoglobulin G1 (IgG1) isotype control (eBioscience) and mouse anti-human JAM-A monoclonal antibody (Santa Cruz), followed by incubation with Dylight488-conjugated goat anti-mouse IgG antibody (BioLegend). Those cells were stained with PI to gate out dead cells.
All stained samples were analyzed using a BD Accuri C6 flow cytometer (BD Biosciences). All given data were analyzed using FlowJo software ver. 10.1 (FlowJo, Ashland, OR, USA).
Western Blotting
Cells were plated at 3 Â 10 5 cells per well in 6-well plates and treated with reovirus (MOI 100) and KU60019 (2.5 mM) for 24 and 48 h. For short-term incubation, CMeC1 cells were plated at 5 Â 10 5 cells per well in 6-well plates, and on the following day, cells were treated as shown above (see Reovirus Replication and Progeny Virus). Harvested cells were lysed at 4 C with NP40 lysis buffer (1% NP40, 10 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA) supplemented with protease inhibitor cocktails (Nacalai Tesque), 1 mM Na 3 VO 4 , and 50 mM sodium fluoride (NaF). The resulting supernatants were collected and used as cell lysates. These lysates were subjected to SDS-PAGE, and proteins then were transferred to Hybond polyvinylidene fluoride (PVDF) membrane (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA). The membrane was blocked with Tris-buffered saline (TBS) containing with 0.05% Tween 20 (polyoxyethylene sorbitane monolaureate) and 5% skim milk, followed by addition of the primary antibodies. The primary antibodies are listed in Table S1 . Horseradish peroxidase (HRP)-conjugated antibodies were used as the secondary antibodies. The labeled proteins were detected using an enhanced chemiluminescence (ECL) reagent (PerkinElmer). The intensity of the bands was determined by ImageJ software ver. 1.48.
LysoTracker Red Staining
CMeC1 cells (1 Â 10 5 cells) were cultured on microcover glasses (Matunami Garasu Kogyo, Osaka, Japan) in the wells of a 12-well plate. On the following day, cells were exposed to reovirus (MOI 100) for 1 h at 4 C. Then, cells were washed and cultured in the presence of KU60019 (2.5 mM) for 24 h at 37 C. After treatment, cells were incubated with LysoTracker red DND-99 (Invitrogen, Carlsbad, CA, USA) for 30 min at 37 C, followed by fixation with 4% paraformaldehyde. The coverslips were mounted onto glass slides with Molecular Probes prolong gold with DAPI (Invitrogen) for staining of nuclei. Samples were visualized at a 100Â magnification using LSM710 confocal microscope (Carl Zeiss, Oberkochen, Germany). Images were analyzed by using ZEN software 2012 (Carl Zeiss). The percentage of LysoTracker red-positive CMeC1 cells was quantified by flow cytometric analysis as described above.
Measurement of Cathepsin B Activity
Cathepsin activity was determined with a cathepsin B activity assay kit (PromoCell, Heidelberg, Germany), according to the manufacturer's instructions. CMeC1 cells were cultured at the density of 5 Â 10 5 cells per well in 6-well plates. Then, cells were treated with reovirus (MOI 100) and KU60019 (2.5 mM) for 24 h. After treatments, cells were lysed with CB cell lysis buffer, followed by mixing with the CB reaction buffer. The cell lysate was incubated at 37 C for 1 h with 200 mM CB substrate Ac-RR-AFC. Cathepsin activity was measured in an ARVO X4 fluorometer (PerkinElmer). The fluorescence values were normalized to values obtained for a mock-treated sample after subtraction of background autofluorescence.
Statistical Analysis
The mean values and SD in each assay were calculated from the mean of at least three biological independent experiments. The significance of differences between samples was determined by the one-way factorial ANOVA test followed by multiple comparison using Tukey-Kramer test. Differences were considered statistically significant if the p values were less than 0.05. Multiple comparison tests were performed using JMP software ver. 9.0 (SAS Institute Japan, Tokyo, Japan).
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